|
|
| |
Drugs and Therapeutics (D & T) Committee
Meeting Results*
March 26, 2008 |
Drug Name |
Review Type |
Committee Recommendation |
Prior Approval Status – Final Determination |
Combigan |
New Drug Initial Review |
Require Prior Approval |
Prior Approval Required |
Iquix |
New Drug Initial Review |
Require Prior Approval |
Prior Approval Required |
Lipofen |
New Drug Initial Review |
Require Prior Approval |
Prior Approval Required |
ProAir HFA |
PDL Appeal |
Remain Non-Preferred |
Non-Preferred – PDL Class |
Saizen |
PDL Appeal |
Remain Non-Preferred |
Non-Preferred – PDL Class |
Sanctura XR |
New Drug Initial Review |
Require Prior Approval |
Prior Approval Required |
Simcor |
New Drug Initial Review |
Require Prior Approval |
Prior Approval Required |
Tekturna |
New Drug Initial Review |
Require Prior Approval |
Prior Approval Required |
Vusion |
New Drug Initial Review |
Require Prior Approval |
Prior Approval Required |
|
 * These results are pending final recommendation by the Illinois State Medical Society (ISMS) Board of Trustees. D & T Committee recommendations are not considered final until they are reviewed and approved by the ISMS Board of Trustees. When the Department receives the final recommendations, the Department’s Web site will be updated at: http://www.hfs.illinois.gov/pharmacy/dt_comm.html
|
|
|
